Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China November 16, 2022

Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunities….

R&D PARTNERSHIPS - Partnering for Progress: How Collaborations Are Fueling Biomedical Advances November 20, 2017

Neil Lesser and Matt Hefner analyze biopharmaceutical partnerships created throughout the past several decades, and based upon a comprehensive database of partnerships formed between 1980 and 2014, they found that R&D-focused partnerships have grown substantially.

EXECUTIVE INTERVIEW - AmerisourceBergen: Partnering With Orphan Product Manufacturers to Drive Commercialization Success February 27, 2017

Amy Grogg, Senior Vice President of Strategy and Commercialization at AmerisourceBergen Specialty Group provides her perspective on the barriers orphan drug manufacturers face and the solutions available to them through strategic partnerships with distributors.

ADVANCED DELIVERY DEVICES - Disruptive Delivery Technology Partnerships Are Key to Pharmaceutical Life Cycle Management January 16, 2017

Michael D. Hooven, MSME, believes in the challenge to deliver innovative therapies that address unmet patient needs while delivering profitable growth, and the industry is responding by embracing disruptive technology that can concurrently help on both fronts and also speed time to market for pharmaceutical products and services.

DATA-SHARING PLATFORM - How to Overcome the Challenge of Differing Digital Maturity Levels in Biopharmaceutical Supply Chains February 29, 2024

David Brick, MS, and Harlan Knapp, MS, review how the efficient and timely delivery of therapeutics with complex manufacturing needs cannot be achieved by simply unifying the entire pharmaceutical landscape within the most advanced digital maturity level. A better approach is to implement a flexible data-sharing platform that can accommodate partners with different data management capabilities.

SPECIAL ROUNDTABLE - Leadership Panel: 4 Trends That Will Have the Most Impact on Drug Development in 2024 January 26, 2024

Contributor Cindy H. Dubin asked some of today’s life science leaders what they expect will have the greatest impact on drug development in 2024 and beyond.

EXECUTIVE INTERVIEW - Samsung Biologics: Exploring The Evolving Biopharma Landscape January 26, 2024

Kevin Sharp, Senior VP & Head of Sales for Samsung Biologics, discusses the evolving biopharma space, exploring current challenges, and the demand for sustainable solutions.

Medigene AG Presents Final Phase 1 Data of TCR-T Cell Therapy in Patients With High-Risk Blood Cancers April 24, 2023

Aevitas Therapeutics Announces Asset Purchase Agreement With 4D Molecular Therapeutics April 24, 2023

EXECUTIVE INTERVIEW - PCI Pharma Services: The Global, Integrated CDMO Partner of Choice April 3, 2023

John Ross, Senior Vice President of Development and Manufacturing at PCI Pharma Services, discusses what it means to be the partner of choice in a very dynamic industry.

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy January 27, 2023

CatSci & Argonaute RNA Partner to Expedite Oligonucleotide Manufacturing for Gene-Silencing Therapeutics July 28, 2021

CatSci Ltd and Argonaute RNA recently announced a chemistry, manufacturing, and control (CMC) development collaboration focused on novel therapeutic oligonucleotides…..

DRUG DEVELOPMENT EXECUTIVE - Enteris BioPharma: How to Build a Preferred CDMO Partner June 1, 2021

Dr. Paul Shields, COO of Enteris BioPharma, discusses the changing face of the CDMO industry and how his company plans to leverage its newly expanded CDMO operations to take advantage of a variety of growth opportunities to build deeper partnerships.

AavantiBio & Catalent Announce Partnership to Support Development & Manufacturing of Gene Therapies  April 29, 2021

AavantiBio and Catalent recently announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA)….

EXECUTIVE INTERVIEW - Enteris BioPharma: Pioneers in Oral Formulation Development September 30, 2020

Dr. Rajiv Khosla, CEO of Enteris BioPharma, discusses how his company’s innovative oral formulation technology is helping the pharmaceutical industry overcome the hurdle of low bioavailability to reshape treatment categories and expand market opportunities with minimal financial and regulatory risks.

PFS MANUFACTURING - Prefilled Syringes & Biologics: The Perfect Partnership of Medicine & Delivery June 4, 2020

Anish Parikh charts the twin rise of biologics and PFS, outlines some of the common challenges associated with filling and dispensing, and discusses how a patient-centric partnership approach can help biopharmaceutical companies shorten the development pathway and ensure a reliable supply of safe, effective medicines for the people who need them.

Deciphera Pharmaceuticals and Zai Lab Limited Announce Exclusive License Agreement June 13, 2019

Fusion Pharmaceuticals Announces $105-Million Financing April 3, 2019

Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, recently announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.

EXECUTIVE INTERVIEW - SK life science: Challenges of Developing Therapies for Neurological Diseases February 28, 2019

Sebby Borriello, Vice President & Chief Commercial Officer, speaks about the challenges and trends surrounding development of therapies for neurological diseases.

DRUG DEVELOPMENT - Cell & Gene Therapies Calling for Innovation in Drug Development August 27, 2018

Lev Gerlovin and Pascale Diesel, PharmD, believe there is significant evidence to indicate that we are entering a golden age of gene and cell therapy development, and while industry works to advance these programs, the debate over new approaches in both structuring and financing clinical research is likely to continue.